PTC Therapeutics

FDA
#FDA #Mitochondria #PTC Therapeutics #Rare disease

FDA rejects PTC Therapeutics’ drug for Friedreich’s ataxia

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) stating its decision not to recommend PTC Therapeutics’ vatiquinone for Friedreich’s ataxia (FA).  The FDA stated in the CRL that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional… Read More

#News #Regulatory

Gene therapy
#FDA #Gene therapy #Neurology #Neuroscience #PTC Therapeutics #Rare disease

FDA approves first gene therapy for rare genetic disorder

The US Food and Drug Administration (FDA) has approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy for the treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the… Read More

#News #Regulatory

Neuronal inclusions in Huntington’s disease
#Huntington's disease #Phase II trial #PTC Therapeutics #Trial data

Positive interim data for Huntington’s disease therapy

PTC Therapeutics has shared interim data from the 12-week portion of the PIVOT-HD Phase II study of PTC518 in Huntington’s disease (HD) patients. The study demonstrated dose-dependent lowering of Huntingtin (HTT) protein levels in peripheral blood cells, reaching a mean 30% reduction in mutant HTT levels… Read More

#News

Duchenne muscular dystrophy
#Muscular dystrophy #National Institute for Health and Care Excellence (NICE) #Paediatrics #PTC Therapeutics #Rare disease

Rare muscular dystrophy drug to be funded in England and Wales

The National Institute for Health and Care Excellence (NICE) has published its Final Guidance recommending Translarna (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales.   Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged two… Read More

#News #Regulatory